#	Aladdin ID	Assay Type	Description	Organism	Compounds	Reference	BAO Format	Source
1.	ALA646172	F	In vivo antineoplastic activity was determined in BDF1 mice implanted with B16 melanoma and activity expressed as T/C at 6.25 mg/kg ip dose (Q1Dx9 treatment)	Mus musculus	1	ALA1123842	organism-based format	Scientific Literature
2.	ALA646173	F	In vivo antineoplastic activity was determined in BDF1 mice implanted with B16 melanoma and activity expressed as T/C at 80 mg/kg ip dose (Q1Dx9 treatment)	Mus musculus	1	ALA1123842	organism-based format	Scientific Literature
3.	ALA646174	F	No. of cures on day 60 at 10 mg/kg (ip) against B16 melanocarcinoma in mice	Mus musculus	2	ALA1122293	organism-based format	Scientific Literature
4.	ALA646175	F	No. of cures on day 60 at 20 mg/kg (ip) against B16 melanocarcinoma in mice	Mus musculus	2	ALA1122293	organism-based format	Scientific Literature
5.	ALA646176	F	No. of cures on day 60 at 40 mg/kg (ip) against B16 melanocarcinoma in mice	Mus musculus	2	ALA1122293	organism-based format	Scientific Literature
6.	ALA646177	F	No. of cures on day 60 at 5 mg/kg (ip) against B16 melanocarcinoma in mice	Mus musculus	2	ALA1122293	organism-based format	Scientific Literature
7.	ALA646178	F	No. of cures on day 60 at 80 mg/kg (ip) against B16 melanocarcinoma in mice	Mus musculus	2	ALA1122293	organism-based format	Scientific Literature
8.	ALA646179	F	Compound was tested in vivo for the antitumor activity against B16 melanocarcinoma at dose level of 25 mg/kg	Mus musculus	1	ALA1123467	organism-based format	Scientific Literature
9.	ALA646180	F	Median survival time of test animals compared to controls at 10 mg/kg (ip) against B16 melanocarcinoma in mice	Mus musculus	2	ALA1122293	organism-based format	Scientific Literature
10.	ALA646181	F	Median survival time of test animals compared to controls at 20 mg/kg (ip) against B16 melanocarcinoma in mice	Mus musculus	2	ALA1122293	organism-based format	Scientific Literature
11.	ALA646182	F	Median survival time of test animals compared to controls at 40 mg/kg (ip) against B16 melanocarcinoma in mice	Mus musculus	2	ALA1122293	organism-based format	Scientific Literature
12.	ALA646183	F	Median survival time of test animals compared to controls at 5 mg/kg (ip) against B16 melanocarcinoma in mice	Mus musculus	2	ALA1122293	organism-based format	Scientific Literature
13.	ALA646184	F	Median survival time of test animals compared to controls at 80 mg/kg (ip) against B16 melanocarcinoma in mice	Mus musculus	2	ALA1122293	organism-based format	Scientific Literature
14.	ALA646185	F	Weight difference at 10 mg/kg (ip)against B16 melanocarcinoma in mice	Mus musculus	2	ALA1122293	organism-based format	Scientific Literature
15.	ALA646186	F	Weight difference at 20 mg/kg (ip) against B16 melanocarcinoma in mice	Mus musculus	1	ALA1122293	organism-based format	Scientific Literature
16.	ALA646187	F	Weight difference at 20 mg/kg (ip)against B16 melanocarcinoma in mice	Mus musculus	1	ALA1122293	organism-based format	Scientific Literature
17.	ALA646188	F	Weight difference at 40 mg/kg (ip)against B16 melanocarcinoma in mice	Mus musculus	2	ALA1122293	organism-based format	Scientific Literature
18.	ALA646189	F	Weight difference at 5 mg/kg (ip)against B16 melanocarcinoma in mice	Mus musculus	2	ALA1122293	organism-based format	Scientific Literature
19.	ALA646190	F	Weight difference at 80 mg/kg (ip) against B16 melanocarcinoma in mice	Mus musculus	2	ALA1122293	organism-based format	Scientific Literature
20.	ALA646191	F	MST of treated animal over control when administered at a dose of 2.5 mg/kg intraperitoneally on Q01Dx01 treatment schedule in B16 melanocarcinoma cell lines	Mus musculus	1	ALA1122504	organism-based format	Scientific Literature